Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560


SEC Filings

PACIRA PHARMACEUTICALS, INC. filed this Form 10-K on 03/01/2017
Entire Document
 << Previous Page | Next Page >>


Common Stock
The Company is authorized to issue up to 250,000,000 shares of common stock, of which 37,480,952 and 36,848,319 were outstanding at December 31, 2016 and 2015, respectively.
In April 2014, the Company completed a follow-on underwritten public offering of 1,840,000 shares of common stock, including the shares issued to cover the underwriters’ overallotment option, at $64.00 per share. The Company received proceeds of $110.5 million as a result of the offering, net of underwriters’ fees and related expenses.
Preferred Stock
The Company is authorized to issue up to 5,000,000 shares of preferred stock. No preferred stock was outstanding at December 31, 2016 or 2015.
The Company had no warrants outstanding at December 31, 2016. At December 31, 2015, the Company had 7,216 warrants outstanding at a weighted average exercise price of $13.44.
Accumulated Other Comprehensive Income (Loss)
The following table illustrates the changes in the balances of the Company’s accumulated other comprehensive loss (in thousands):
Net Unrealized Gains
(Losses) From Available
For Sale Investments
Balance at December 31, 2014
Other comprehensive income before reclassifications

Amounts reclassified from accumulated other comprehensive income (loss)

Balance at December 31, 2015
Other comprehensive income before reclassifications

Amounts reclassified from accumulated other comprehensive income (loss)

Balance at December 31, 2016
Stock Incentive Plans
The Company’s amended and restated 2011 stock incentive plan, or 2011 Plan, was adopted by its Board of Directors and approved by its stockholders in June 2014. The 2011 Plan allows the granting of incentive stock options, non-statutory stock options, restricted stock awards and other stock-based awards. Since the adoption of the 2011 Plan, any remaining shares available for issuance under a 2007 stock incentive plan, or 2007 Plan, are reallocated to the 2011 Plan. In April 2014, the Company’s Board of Directors adopted the 2014 Inducement Plan which authorized 175,000 shares of common stock to be granted as equity awards to new employees.
In June 2016, the Company’s board of directors adopted an amendment to the 2011 Plan. Under the amendment, an additional 4,000,000 shares of common stock were authorized for issuance as equity awards under the plan. The amendment to the 2011 Plan was subsequently ratified by the Company’s stockholders and became effective in June 2016.
All of the Company’s stock option grants have an exercise price equal to the closing price of the Company’s common stock on the date of grant, generally have a 10-year contractual term and vest in increments (generally over four years from the date of grant although the Company may occasionally grant options with different vesting terms). Since 2015, the Company has granted RSUs to employees and its Board of Directors. The Company uses authorized and unissued shares to satisfy its obligations under these plans.

F- 23

 << Previous Page | Next Page >>

Contact Investor Relations:
Susan Mesco
(973) 451-4030

IHI/NPSF Project Seeks to Improve the Assessment and Management of Acute Pain
Click here for more...